Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
169
resultados
Última actualización
28/04/2025 [07:03:00]
Resumen de: WO2025085665A1
A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Resumen de: US2025127734A1
Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta+2 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.
Resumen de: US2025127744A1
The present invention relates to treating SARS-CoV-2 infection by concurrent administration of different treatment supplementation through anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The lower doses of the proposed treatment modalities in the present invention denoted anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The higher doses of the proposed treatment modalities in the present invention promoted the release the CD4+ and CD8+ T cell, increasing the phagocytosis activity for viral clearance of SARS-CoV-2 infection. The proposed treatment modalities in the present invention allow the maturation of antibodies against natural SARS-CoV-2 infection.
Resumen de: US2025130227A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: US2025130230A1
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
Resumen de: US2025130231A1
The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.
Resumen de: US2025129165A1
The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.
Resumen de: US2025127881A1
The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.
Resumen de: US2025127880A1
Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.
Resumen de: US2025127890A1
Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.
Resumen de: US2025129438A1
A method of detecting SARS-CoV includes amplifying isothermally a target sequence in a sample with at least one set of oligonucleotide primers and assaying the sample with a SARS assay to detect the target sequence of a SARS-CoV nucleic acid sequence. A kit for detecting SARS-CoV in a sample includes a reverse transcriptase, a universal primer set suitable for loop-mediated isothermal amplification (LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof containing mutations within one or more primer binding sites.
Resumen de: US2025129368A1
The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-COV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5′ terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-COV-2.
Resumen de: AU2023356620A1
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: WO2025084921A1
The present invention relates to the development of formulations based on the glycyrrhizic acid compound due to its antiviral, anti-inflammatory and immunomodulatory properties, as a syrup at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, as a solution for nebulising at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, and as a spray of liposomal nanoparticles at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound. Cough suppressants, bronchospasm inhibitors and anti-corticoids are added, and lastly, the pH is adjusted in a range of 4 - 7 as this is the most physiological range. The invention is for the therapeutic and prophylactic management of infections and clinical symptoms of the infection due to SARS-CoV2 and COVID-19.
Resumen de: WO2025083216A1
The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.
Resumen de: GB2634804A
A method for predicting an interaction between a receptor-binding domain (RBD) in a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a human angiotensin-converting enzyme 2 (hACE2) receptor comprises conducting prediction simulation based on a protein structure data and comparing an obtained prediction result with surface plasmon resonance (SPR) experimental data; analysing protein structure simulation and binding simulation based on a sequence data; and analysing protein structure simulation and binding simulation based on a mutation site. The method is based on PROtein binDIng enerGY prediction (PRODIGY) and can predict an interaction mode between the RBD in the S protein and the hACE2 receptor through multiple data types, and can quickly and effectively analyse the infectivity.
Resumen de: WO2023242246A1
The present invention relates to methacrylate-based functionalized dendronized polyglycerol polymers. These polymers are highly biocompatible and less anticoagulant, form thread-like single chain fibers and show excellent inhibition against respiratory viruses such as SARS-CoV-2 and HSV-1. They can be easily used for forming degradable hydrogels together with a crosslinker.
Resumen de: GB2634841A
A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump. The architecture of the neutered inactivated virus can be kept intact or partially destroyed by using graded dosage of the UVC.
Resumen de: US2021311054A1
The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-COV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.
Resumen de: US12281155B1
The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).
Resumen de: WO2025080149A1
A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.
Resumen de: WO2025080150A1
The invention relates to a kit comprising a primer pair and optionally probe(s) for assaying the presence of two genetic polymorphisms, namely rs143334143 locus and at the rs74956615 whose occurrence significantly modifies the course of (indicates the risk of a severe) COVID-19 disease. The invention also relates to a method with the same purpose. The kit and the method represent new tools in the public health protection against COVID-19 disease.
Resumen de: US2025123269A1
A robust human cell culture model permissive to both SARS-COV-2 variants and MERS-COV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-COV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-COV-2 spike protein. By contrast, MERS-COV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549-ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 (“ACE2plusC3D4”) are highly susceptible to MERS-COV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Resumen de: WO2025081000A1
To infer transmission links using within-host variation, Applicants first developed a statistical model of minor variant frequencies, which Applicants fit to a dataset of 134,682 SARS- CoV-2 genomes from Massachusetts, USA. Applicants then combined this model with a stochastic epidemic process to develop a hierarchical Bayesian statistical model of viral outbreaks. After validating the approach on both synthetic and real outbreak datasets, Applicants applied the tool to 5,692 outbreak clusters among the 134,682 Massachusetts genomes. Applicants found that informative sub-consensus variants are relatively rare in outbreaks, but that when they do occur, they significantly help resolve transmission networks. Applicants methods and results demonstrate the utility of within-host variation for transmission inference of SARS-CoV-2 and other pathogens, stressing the importance of pathogen sequencing in epidemiology and public health.
Nº publicación: US2025121052A1 17/04/2025
Solicitante:
GRITSTONE BIO INC [US]
Gritstone bio, Inc
Resumen de: US2025121052A1
Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
BOPI
Sede Electrónica
